ISB News

ISB Post Doc Gets Patent for Protein that Blocks HIV

MartinShelton
Martin Shelton

Martin Shelton, a post doc in the Lee Hood lab, just received his first patent. He shared the following explanation with his 10-year-old nephew who’s a burgeoning scientist/inventor/engineer.

“We made a small molecule called a peptide (which is a sciency word for a piece of a protein). This peptide blocks a function that is key to the spread of the Human Immunodeficiency Virus (HIV, the virus that causes AIDS) within a person by trapping the virus within the infected cell and preventing it from infecting surrounding cells. It knocks out a similar function in cancer that could hinder tumor growth and the spread of cancer from one part of the body to another. We think it could one day be used to help treat HIV/AIDS or cancer, but it still has a long way to go and would have to pass many, many more tests before it could be used as a medicine. But in the meantime, it’s a useful tool for studying certain aspects of these diseases.”

Congratulations, Martin!

20130502-184513.jpg

Recent Articles

  • Spotlight on ISB Education graphic

    2023-24 School Year ISB Education Highlights

    Each month throughout the 2023-2024 academic year, we will highlight some of the top projects the ISB Education team is working on. In March, ISB Education highlights include a paper published in a Nature Portfolio journal, two events for science/STEM leaders, and more.

  • STEM Program Models for Students from Historically Marginalized Communities

    A new study unveils important insights and actionable protocols into providing equitable STEM experiences for high school students from historically marginalized communities. The research highlights the transformative power of informal STEM learning and the ease with which many organizations could provide these opportunities.

  • Common Immune Response Protective Across Many Diseases

    Infection, autoimmunity and cancer account for 40 percent of deaths worldwide. In a Cell Reports paper, ISB researchers detail how the human immune system works in common ways across diseases – findings that offer promising avenues for exploring multi-disease therapeutic strategies.